Anthony Wile, CEO of PharmaCielo Ltd. (“the Company”) is pleased to announce that David Gordon has been appointed its Chief Corporate Officer (CCO) effective October 1, 2018.

As CCO, Mr. Gordon will be responsible for overseeing and managing relationships with news media, analysts, shareholders and regulators in addition to ensuring alignment in achieving corporate responsibility and development objectives across international operations.


David Gordon appointed Chief Corporate Officer of PharmaCielo (CNW Group/PharmaCielo)
David Gordon appointed Chief Corporate Officer of PharmaCielo (CNW Group/PharmaCielo)

“David has been an essential advisor to PharmaCielo since the earliest days of its establishment, guiding us on effective communication and corporate development strategies,” said Anthony Wile.  “As we build out our global infrastructure, I am delighted that he has agreed to bring his impressive track record and range of experience to the table on a permanent basis to help us to continue the growth and expansion of PharmaCielo throughout both the Colombian and international marketplace.”

Previously Mr. Gordon was a principal advisor to PharmaCielo as Managing Partner of Cohn & Wolfe | Canada, one of Canada’s leading communication strategy firms, and since 2013 has served as Chair of the Canadian Council of PR Firms.  Mr. Gordon was appointed to the Board of Directors of PharmaCielo Ltd. in 2016 and is a member of the Institute of Corporate Directors (ICD).

“Working with PharmaCielo and the executive team for the past several years has been an exciting period.  The emergence of a new industry that challenges convention on multiple levels including international trade, public policy and communication, to name but a few, encapsulates the various fields of challenge I have experienced throughout my career,” said David Gordon. “I look forward to continuing to work with my colleagues in Canada and Colombia to help expand to the global market the leadership that PharmaCielo has demonstrated in the Colombian marketplace.”

With 20-plus years of experience in corporate strategy and brand communications, combined with a background in public policy and political strategy following a career start in international trade and combined with an MA and MBA, David Gordon is a strong believer in being an engaged member of the community and has served on the boards of a number of non-profit organizations.

About PharmaCielo

PharmaCielo Ltd. is a global company privately held and headquartered in Canada, with a focus on processing and supplying all natural, medicinal-grade cannabis oil extracts and related products to large channel distributors. PharmaCielo’s principal (and wholly owned) subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered at its Nursery and Propagation Centre located in Rionegro, Colombia.

The boards of directors and executive teams of both PharmaCielo and PharmaCielo Colombia Holdings are comprised of a diversely talented group of international business executives and specialists with relevant and varied expertise. PharmaCielo recognized the significant role that Colombia’s ideal location will play in building a sustainable business in the medical cannabis industry, and the company, together with its directors and executives, has built a compelling business plan focused on supplying the international marketplace.

For further information:

www.PharmaCielo.com  

For further information: Media Relations: David Gordon, Tel: +1 647 259 3258, d.gordon@pharmacielo.ca; (Colombia) Juan Manuel Cuellar, Tel: +57 310 3298776, Juan.M.Cuellar@Sprgroup.biz

Source: www.newswire.ca

Trulieve Cannabis Corp. (“Trulieve” or the “Company”) (CSE: TRUL) (OTCQX: TCNNF), a leading and top-performing cannabis company in the United States today announced the appointment of Marcum LLP (“Marcum”) as its independent registered public accounting firm, effective July 5, 2021 . Marcum was appointed following the resignation of MNP LLP (“MNP”) as the Company’s independent registered public accounting firm effective July 5, 2021 .

“We would like to thank MNP for their guidance and expertise over the past two years and we look forward to working with Marcum as the Company’s new independent registered public accounting firm,” stated Chief Financial Officer, Alex D’Amico.

Keep reading... Show less

Cannabis-infused beverages are not a new product concept, but this summer Canadian drink makers hope consumers will discover them for the first time.

Recreational cannabis beverages have beguiled Canadian producers through different avenues, and many continue to make investments. The promise of these drinks lies in the potential of a more welcoming option for new consumers who may be out of their depth with rolled-up dried flower.

Keep reading... Show less

In the news release, BioHarvest Sciences Inc.‘s First Cannabis Cell Reservoir Produces Ongoing Flowering Stage Cannabinoid Cells For 2 Years, issued 07-Jul-2021 by BioHarvest Sciences Inc. over PR Newswire, we are advised by the company that an incorrect version of the release was issued inadvertently. The complete, corrected release follows:

BioHarvest Sciences Inc.‘s First Cannabis Cell Reservoir Produces Ongoing Flowering Stage Cannabinoid Cells For 2 Years

Keep reading... Show less

Trulieve is the first medical cannabis operator to start planting in the state

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today that it commenced operations in West Virginia . The Company has begun cultivation at their 100,000 square foot size facility in Huntington, West Virginia .

Keep reading... Show less

– The Company demonstrates the efficiency and reliability of its BioFarming technology by reducing production cycle time for Cannabis from 14-23 weeks to 3-4 weeks.

– The Company’s BioFarming technology will allow the Company to harvest 13-17 cycles per year versus 2-4 cycles per year for conventional Cannabis agriculture.

Keep reading... Show less